Sonoma Pharmaceuticals, Inc. Common Stock
Symbol: SNOA (NASDAQ)
Company Description:
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
- Today's Open: $4.08
- Today's High: $4.209
- Today's Low: $4.015
- Today's Volume: 10.80K
- Yesterday Close: $4.2
- Yesterday High: $4.2762
- Yesterday Low: $3.802
- Yesterday Volume: 100.47K
- Last Min Volume: 0
- Last Min High: $4.162
- Last Min Low: $4.156
- Last Min VWAP: $0
- Name: Sonoma Pharmaceuticals, Inc. Common Stock
- Website: https://www.sonomapharma.com
- Listed Date: 2007-01-25
- Location: BOULDER, CO
- Market Status: Active
- CIK Number: 0001367083
- SIC Code: 3841
- SIC description: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
- Market Cap: $7.28M
- Round Lot: 100
- Outstanding Shares: 1.64M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-08-29 | 8-K | View |
2025-08-07 | 10-Q | View |
2025-07-11 | DEF 14A | View |
2025-06-20 | 4 | View |
2025-06-20 | 4 | View |
2025-06-20 | 4 | View |
2025-06-20 | 4 | View |
2025-06-17 | S-8 | View |
2025-06-17 | 10-K | View |
2025-04-28 | 8-K | View |
2025-04-07 | 8-K | View |
2025-03-25 | 8-K | View |
2025-02-05 | 10-Q | View |
2025-01-30 | 8-K | View |
2025-01-03 | 4 | View |
2025-01-03 | 4 | View |
2025-01-03 | 4 | View |
2025-01-03 | 4 | View |
2025-01-03 | 4 | View |
2025-01-03 | 4 | View |